SK pharmteco, a global CDMO, has announced a $260 million investment to build a new manufacturing facility in Sejong, South Korea. The state-of-the-art facility, set to begin operations in 2026, will increase the company’s capacity to produce small molecules and peptides, critical components for innovative therapies. Spanning 135,800 square feet, the facility will house eight production lines and advanced R&D facilities, supporting both clinical and commercial production.
This investment reflects SK pharmteco’s strategic commitment to expanding its global manufacturing capabilities, with plans to hire over 300 employees at the new site. The expansion also includes preparations for a future sixth plant to quickly scale capacity as needed.
The facility aims to address industry challenges, including limited global manufacturing capacity and regulatory complexity, by offering scalable, high-quality production solutions. As the life sciences sector continues to grow, SK pharmteco’s expansion strengthens its position as a reliable partner for companies developing cell and gene therapies and other cutting-edge treatments.
